Payment overview · 2025
General Payments
$235.15
14 reported records · 8 companies
Healthcare provider profile · identity verified
Jean Pringle, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREAT BEND, KS · NPI 1912957580
Verified facts
What the public records show
CMS Open Payments records show Jean Pringle, M.D. received $235.15 in general payments during 2025 across 14 reported records.
Abbott Laboratories accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.46 | 19.8% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.00 | 19.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.14 | 16.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.37 | 14.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.04 | 9.4% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $18.59 | 7.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.58 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.97 | 5.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $235.15 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.46 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $46.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.37 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $18.59 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 39 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
39 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 546 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 74 |
| Gabapentin | Gabapentin | 299 | 65 |
| Potassium Chloride | Potassium Chloride | 253 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 230 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 48 |
| Sertraline Hcl | Sertraline Hcl | 190 | 42 |
| Metformin Hcl Er | Metformin Hcl | 189 | 51 |
| Losartan Potassium | Losartan Potassium | 179 | 54 |
| Omeprazole | Omeprazole | 176 | 44 |
| Furosemide | Furosemide | 174 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 46 |
| Spironolactone | Spironolactone | 138 | 34 |
| Clonazepam | Clonazepam | 134 | 15 |
| Lisinopril | Lisinopril | 116 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 31 |
| Montelukast Sodium | Montelukast Sodium | 106 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 22 |
| Famotidine | Famotidine | 98 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 16 |
| Finasteride | Finasteride | 94 | 23 |
| Simvastatin | Simvastatin | 92 | 26 |
| Alendronate Sodium | Alendronate Sodium | 89 | 20 |
| Allopurinol | Allopurinol | 88 | 20 |
| Enalapril Maleate | Enalapril Maleate | 88 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 24 |
| Tramadol Hcl | Tramadol Hcl | 82 | 18 |
| Carvedilol | Carvedilol | 75 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 24 |
| Donepezil Hcl | Donepezil Hcl | 71 | 14 |
| Mirtazapine | Mirtazapine | 70 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 20 |
| Xarelto | Rivaroxaban | 65 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 64 | 12 |
| Prednisone | Prednisone | 60 | 31 |
| Lorazepam | Lorazepam | 56 | 14 |
| Bumetanide | Bumetanide | 55 | suppressed |
| Eliquis | Apixaban | 50 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 48 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Atenolol | Atenolol | 47 | 14 |
| Ozempic | Semaglutide | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Klor-Con M20 | Potassium Chloride | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 39 | 33 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Nystatin | Nystatin | 27 | 16 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 13 |
| Meloxicam | Meloxicam | 24 | 11 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 23 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Digoxin | Digoxin | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Cartia Xt | Diltiazem Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Lactulose | Lactulose | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Etodolac | Etodolac | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $235.15 · 14 records | Abbott Laboratories | FARXIGA, FREESTYLE LIBRE 3, LEQVIO, MOUNJARO, Ozempic, REXULTI, Rybelsus, SHINGRIX, SMARTVEST, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error